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The purpose of this study was to investigate the eﬀect of KCNQ (potassium channel, voltage-gated, KQT-like subfamily) openers
in preventing myotonia caused by anthracene-9-carboxylic acid (9-AC, a chloride channel blocker). An animal model of myotonia
can be elicited in murine skeletal muscle by 9-AC treatment. KCNQ openers, such as retigabine and ﬂupirtine, can inhibit the
increased twitch amplitude (0.1Hz stimulation) and reduce the tetanic fade (20Hz stimulations) observed in the presence of 9-
AC. Furthermore, the prolonged twitch duration of skeletal muscle was also inhibited by retigabine or ﬂupirtine. Lamotrigine (an
anticonvulsant drug) has a lesser eﬀect on the muscle twitch amplitude, tetanic fade, and prolonged twitch duration as compared
with KCNQ openers. In experiments using intracellular recordings, retigabine and ﬂupirtine clearly reduced the ﬁring frequencies
of repetitive action potentials induced by 9-AC. These data suggested that KCNQ openers prevent the myotonia induced by 9-AC,
at least partly through enhancing potassium conductance in skeletal muscle. Taken together, these results indicate that KCNQ
openers are potential alternative therapeutic agents for the treatment of myotonia.
1.Introduction
KCNQ(potassiumchannel,voltage-gated,KQT-likesubfam-
ily)potassiumchannels(Kv7)playamajorroleincontrolling
membrane excitability and thus represent interesting drug
targets for the treatment of epilepsy and neuropathic pain.
[1–3]. To date, in mammals, ﬁve members of the KCNQ
family have been reported [1]: Kv7.1 to Kv7.5. These are
potassium (K+) channel proteins that are widely distributed
inthebrain,innerear,heart,pancreas,lung,andplacenta[4–
8]. Retigabine and ﬂupirtine, voltage-dependent KCNQ K+
channel (Kv.7) openers, exert anticonvulsant and analgesic
actions in the central nervous system [9–11]. Retigabine
also has antinociceptive eﬀects in rat models of persistent
and chronic pain. The antinociceptive eﬀects associated with
retigabine administration were reversed by coadministration
of KCNQ blockers [10–13]. Flupirtine, a compound that is
structurally similar to retigabine, enhances the activation of
KCNQ K+ channels. This drug can prevent and suppress
seizures in both the kainic acid and ﬂurothyl models of
symptomatic neonatal seizures [14] and is a centrally-
acting, nonopioid analgesic that may prove useful in the
treatment of a variety of pain states [15]. In addition to
anticonvulsant and analgesic eﬀects, several studies have
shown that retigabine and ﬂupirtine exert neuroprotective
eﬀects on central neurons [16–20]. Recent studies have
reported that Kv7.1 [21]a n dK v 7 . 5[ 22, 23] transcripts are
expressed in adult skeletal muscle. Transcript levels of Kv7.1
and Kv7.5 are increased during in vitro proliferation and
diﬀerentiation of rat myoblasts [24]. More recently, Iannotti
et al. [25] showed that Kv7 K+ channels are expressed in
diﬀerentiating C2C12 cells and myotubes [25]. However,
the functional role of KCNQ K+ channels in mammalian
skeletal muscle remains unknown. K+ channels may play a
role in the patterns of muscle contraction and relaxation
and potentially modulate the resting membrane potential2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of retigabine and ﬂupirtine on the anthracene-9-carboxylic-acid (9-AC)-induced myotonia. Representative muscle
contraction traces recorded from mouse phrenic nerve-diaphragm preparations are shown in (a)–(c). The addition of 9-AC (0.1mM)
increased the amplitude of muscle contractions. Treatment with retigabine (0.03mM, (a)) and ﬂupirtine (0.03mM, (b)) resulted in an
inhibition of the increased amplitude of muscle contractions induced by 9-AC. Lamotrigine (0.03mM) has no inhibitory eﬀect on the
muscle amplitude induced by 9-AC (c). (d) Dose-response eﬀects of retigabine, ﬂupirtine, and lamotrigine on 9-AC-induced myotonia.
P e r c e n to fc o n t r o l(y-axis): the twitch amplitude ratio of after treatment (retigabine, ﬂupirtine, or lamotrigine) to before treatment (9-AC
alone).
of skeletal muscle cells [26]. In addition to K+ channels,
chloride (Cl−) conductance accounts for more than 70%
of the resting conductance in mammalian skeletal muscle.
Myotonia occurs naturally in several species (humans, goats,
mice) as a result of a genetic deﬁciency in the skeletal
muscle CLC-1 Cl− channel, a disease termed myotonia
congenita in humans [27–30]. An animal model of myotonia
in mammalian skeletal muscle can be induced by treatment
with the Cl− channel blocker 9-anthracene carboxylic acid.
In the present studies, the eﬀects of KCNQ K+ openers on
Cl− channel blocker-induced myotonia were investigated.
It was found that KCNQ K+ openers but not lamotrigine
(an anticonvulsant drug with no eﬀect on KCNQ channel
activity) inhibited muscle myotonia and the ﬁring frequency
of repetitive action potentials induced by the Cl− channel
blocker.
2.MaterialsandMethods
2.1. Mouse Phrenic Nerve-Diaphragm Preparations. ICR
strain mice (17–22g) were sacriﬁced inhaled carbon dioxide.
Phrenic nerve-diaphragm preparations were isolated and
suspended in an organ bath containing 10mL modiﬁed
Krebs’ solution at 36 ± 1◦C and oxygenated with carbogen
(95% O2 +5% CO 2). The composition of the modiﬁed
Krebs’ solution was the following (in mM): NaCl (131), KClEvidence-Based Complementary and Alternative Medicine 3
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Figure 2: The eﬀects of retigabine, ﬂupirtine and lamotrigine on the statistical time-course curves of indirect-(nerve) and direct-(muscle)
stimulated muscle contractions induced by 9-AC (0.01mM). (a)–(c) and (d)–(f) are the muscle tensions elicited by indirect and direct
stimulation at 0.1Hz, respectively. Retigabine (0.03mM, (a, d)) and ﬂupirtine (0.03mM, (b, e)), but not lamotrigine (0.03mM, (c, f)),
signiﬁcantly inhibited the 9-AC-induced increase in muscle amplitude. 9-AC was applied at time zero. Retigabine, ﬂupirtine, or lamotrigine
was applied at time 15min. ∗P<0.01 as compared with 9-AC treatment alone. Control: no chemical treatment.
(4.8), MgSO4 (1.2), CaCl2 (1), NaHCO3 (12.5), and glu-
cose [11], with pH of 7.40 ± 0.1 when oxygenated. The
isolated diaphragm was initially rinsed 3-4 times with
the modiﬁed Krebs solution. Each isolated diaphragm was
stretchedtooptimallengthbyapplyingapreloadforceof2g,
and the peak isometric twitch tension was measured during
indirect (phrenic nerve) or direct (muscle) stimulation.
Stimulation was performed with a supramaximal constant-
voltage pulse (a duration of 0.02ms for indirect and 0.5ms
for direct stimulation) using a Grass S88 stimulator. Tetanic
muscle contraction was achieved by using supramaximal
stimulation at 20Hz with a 3s train duration. The phrenic
nerve was stimulated electrically through a circular bipolar
platinum electrode when indirect twitch tension was elicited.
A pair of linear bipolar platinum stimulating electrodes was
used when direct stimulation was performed. When direct
stimulation was performed, the diaphragm was pretreated
with 50µM d-TC to block the eﬀect of the nerve and the
inﬂuence of nerve stimulation. Contractions were recorded
isometrically with a Grass force-displacement transducer
(FT. 03C) on a Gould TA240 polygraph. The tetanic con-
traction maintenance (TCM) index was calculated as the
last peak tension/initial peak tension. TD50 (twitch duration
50%) was calculated as the twitch duration at 50% of the
amplitude. The stability of the twitch tension for at least
20–30min was conﬁrmed before further experimental pro-
cedures.
2.2. Action Potentials Recordings. Isolated diaphragms were
pinned out on a Sylgard (Dow Corning Corporation, USA)
plate at the bottom of a recording chamber, which con-
tained oxygenated modiﬁed Krebs solution. Transmembrane
action potentials were measured by an intracellular glass
microelectrode with a high impedance ampliﬁer (Axoclamp
2B, Axon Instruments, USA) in bridge mode. Borosilicate
microelectrodes (GC150, Warner, USA) were fabricated
using a Sutter P87 electrode puller (Sutter Instruments,
USA). Glass microelectrodes were ﬁlled with 3mol/L KCl4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: The eﬀects of retigabine, ﬂupirtine, and lamotrigine on the duration of isometric twitches induced by 9-AC (0.1mM). The
representativetracesofmuscletwitchesshowedtheeﬀectsofretigabine(0.03mM,(a)),ﬂupirtine(0.03mM,(b)),andlamotrigine(0.03mM,
(c)) on the prolonged duration of muscle twitches induced by 9-AC. Retigabine and ﬂupirtine shortened the duration of muscle twitches in
the presence of 9-AC. Linopirdine (0.05mM), a KCNQ blocker, antagonises the eﬀects of retigabine and ﬂupirtine on the duration of muscle
twitches. ∗a high-resolution time scale: 200msec.
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Figure 4: Statistical bar graph of the eﬀects of KCNQ openers, lamotrigine and linopirdine (0.05mM) on the twitch duration (TD50)o ft h e
muscle induced by 9-AC (0.1mM). Control: no chemical treatment; 9-AC: 9-AC treatment alone; Ret: retigabine (0.03mM); Flu: ﬂupirtine
(0.03mM); Flu-lino: ﬂupirtine plus linopirdine; Lam: lamotrigine; Lam-lino: lamotrigine plus linopirdine. TD50: twitch duration at 50% of
the amplitude. #P<0.05 as compared with 9-AC alone; ∗P<0.01 as compared with retigabine (ret) or ﬂupirtine (ﬂu); N.S: no signiﬁcance.
and had impedances between 10–15MΩ. Single or multiple
action potentials were evoked by intracellular injection of
depolarising current pulses (20nA; 200ms). The signals of
membrane potentials and action potentials were digitised
at 20–100kHz and stored using DigiData 1322A (Axon
Instruments). Data were analysed using the pClamp 9.0
software (Axon Instruments).
2.3. Drugs and Chemicals. Retigabine was purchased from
LKT laboratories (USA). Flupirtine, and lamotrigine were
purchased from Tocris Bioscience, Inc. (UK). D-tubo-
curarine was purchased from Fluka Inc. (USA). Retigabine,
Flupirtine and lamotrigine were dissolved in dimethyl sul-
foxide (DMSO); d-tubocurarine was dissolved in distilled
water.Evidence-Based Complementary and Alternative Medicine 5
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Figure 5: The eﬀects of retigabine, ﬂupirtine and lamotrigine on repetitive muscle contractions evoked by indirect (nerve)- and direct
(muscle)- stimulation at a frequency of 20Hz in the presence of 9-AC (0.1mM). (a)–(c) and (d)–(f) are the muscle contractions evoked by
the indirect and direct stimulation at a frequency of 20Hz with 3sec duration, respectively. (a, d): retigabine (0.03mM); (b, e): ﬂupirtine
(0.03mM); (c, f): lamotrigine (0.03mM). TCM index: tetanic contraction maintenance index. ∗P<0.01 as compared with 9-AC alone; N.S:
no signiﬁcance.
2.4. Statistics. The data are provided as the mean ±S.E.M.
Statistically signiﬁcant of diﬀerences were evaluated using
a paired or unpaired Student’s t-test. When more than
one group was compared with one control, signiﬁcance
was evaluated using one-way analysis of variance (ANOVA).
Probability values (P) less than 0.01 were considered signiﬁ-
cant.
3. Results
3.1. Eﬀects of KCNQ Openers on the Muscle Contractions
Induced by Anthracene-9-Carboxylic Acid (9-AC). 9-AC, a
potent myotonia inducer, can cause increased membrane
exicabibity and slowed muscle relaxation. The application
of 9-AC (0.1mM) caused an increase in twitch amplitude
under direct stimulation conditions at a frequency of 0.1Hz
(Figure 1). Treatment with retigabine (Ret; Figure 1(a)), and
Flupirtine (Flu; Figure 1(b)) but not lamotrigine (Lam;
Figure 1(c)) signiﬁcantly inhibited the increased amplitude
of muscle contraction induced by 9-AC. Figure 1(d) shows
the dose-response relationship of KCNQ openers and lam-
otrigine. Figure 2 shows the time course of muscle force
responses to indirect (Figures 2(a)–2(c)) and direct (Figures
2(d)–2(f)) stimulation. The eﬀects of retigabine and Flupir-
tine on the response of 9-AC-treated muscle are similar in
bothindirect(vianerve)anddirect(viamuscle)stimulation.
The maximal twitch amplitudes induced by 9-AC from
three independent experiments groups were 188.3 ± 28.4,
166.2±6.0, and 192.4±9.6% of the control. Treatment with
the KCNQ openers retigabine (Figures 2(a) and 2(d)) and
ﬂupirtine (Figures 2(b) and 2(e)), but not the anticonvulsant
drug lamotrigine (182.4 ± 10.1%; Figures 1(c) and 2(f)),
signiﬁcantly inhibited the twitch amplitude induced by 9-
AC (indirect stimulation: from 167.7 ± 15.8t o9 1 .1 ± 9.2%
for Ret and 176.1 ± 20.7 to 119.9 ± 9.7% for Flu; direct
stimulation: from 188.3 ± 28.4t o1 0 4 .4 ± 6.9% for Ret and
166.2±6.0to115.65±3.5%forFlu).Theprolongationofthe
relaxation period in skeletal muscle induced by 9-AC (TD50:
386.6 ± 50.1ms) is also signiﬁcantly inhibited by treatment
with retigabine (31.3±1.9ms) and ﬂupirtine (29.3±3.2ms)
(Figures 3 and 4). Linopirdine (Lino), a KCNQ blocker,
reversed the eﬀects of retigabine and ﬂupirtine on the twitch
duration (TD50) induced by 9-AC (Ret+Lino: 167.1 ±
19.5ms; Flu + Lino: 155.0 ± 40.3ms). Lamotrigine inhibits6 Evidence-Based Complementary and Alternative Medicine
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Figure 6: The eﬀects of retigabine, ﬂupirtine, and lamotrigine on the ﬁring frequency of repetitive action potentials induced by 9-AC
(0.1mM). A train of muscle action potentials was triggered by a depolarising current injection (20nA, 200msec) through the recording
pipette. The eﬀects of retigabine (0.03mM), ﬂupirtine (0.03mM), and lamotrigine (0.03mM) on the ﬁring frequency of action potentials
induced by 9-AC are shown in (a, b, and c), respectively. ∗P<0.01 as compared with 9-AC alone.
the prolonged relaxation period induced by 9-AC to a lesser
extent than retigabine or ﬂupirtine do (Figure 4). However,
linopirdine cannot reverse the eﬀects of lamotrigine on the
inhibition of twitch duration induced by 9-AC (Figure 4).
3.2. Eﬀects of KCNQ Openers on the Muscle Contractions
I n d u c e db y9 - A Ca t2 0 H zS t i m u l a t i o n .In the skeletal
muscle without any chemical treatment, the typical tetanic
contractionmaintenance(TCM)indexbydirectandindirect
stimulation at 20Hz ranged from 1.28–1.47 (1.31 ± 0.03
for indirect stimulation, n = 18; 1.43 ± 0.08 for direct
stimulation; Figures 5(a)–5(f)). The application of 9-AC
caused a fade of tetanic contractions (muscle unable to
sustain a contraction continuously) both in response to
indirect (Figures 5(a)–5(c)) and direct (Figures 5(d)–5(f))
stimulation at 20Hz (TCM index: 0.53 ± 0.04 for indirect
stimulation, n = 21; 0.51 ± 0.05 for indirect stimulation,
n = 21). Treatment with retigabine and ﬂupirtine, but
not lamotrigine, can reverse the fade of tetanic contractions
induced by 9-AC. The TCM index values of 9-AC-treated
diaphragm increase from 0.50 ± 0.04 to 1.34 ± 0.09 for
indirect stimulation and 0.49 ± 0.03 to 1.33 ± 0.05 for
direct stimulation after retigabine treatment; additionally,
ﬂupirtine treatment increases TCM index values from 0.50±
0.03 to 0.99 ± 0.09 for indirect stimulation and 0.50 ± 0.03
to 1.14 ± 0.05 for direct stimulation (Figure 5). Treatment
with lamotrigine cannot reverse the TCM index values of 9-
A C - t r e a t e dd i a p h r a g m s ,w h i c hw e r eo b s e r v e da s0 .60 ± 0.04
to 0.36 ± 0.05 for indirect stimulation and 0.55 ± 0.09 to
0.34 ±0.04 for direct stimulation.
3.3. Eﬀects of KCNQ Openers on the Frequency of Action
Potentials Induced by 9-AC. The mean frequencies of action
potentials of sarcolemma evoked by a depolarisation square
pulse stimulation (20nA, 0.2sec) without any chemical
treatment are 1.27 ± 0.13, 1.53 ± 0.18, and 1.55 ± 0.31Hz
in the three experimental groups, respectively (Figures 6(a)–
6(c): control). The application of 9-AC (0.1mM) to skeletal
muscle ﬁbres increased the ﬁring frequency of repetitive
actionpotentials(38.7±1.9,32.7±1.8and32.4±1.3Hzinthe
three experimental groups, resp.) (Figures 6(a)–6(c): 9-AC).
Retigabine (Figure 6(a)) and Flupirtine (Figure 6(b)), but
not lamotrigine (Figure 6(c)), signiﬁcantly inhibit the ﬁring
frequency of action potentials induced by 9-AC (retigabine:Evidence-Based Complementary and Alternative Medicine 7
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Figure 7: The eﬀects of retigabine, ﬂupirtine, and lamotrigine on the maximum rise slope of action potentials. The eﬀects of retigabine
(0.03mM), ﬂupirtine (0.03mM), and lamotrigine (0.03mM) on the maximum rise slope of action potentials are shown in (a, b, and c),
respectively. ∗P<0.01 as compared with before the chemical treatment.
from 38.7±1.9t o7 .5±0.9Hz; ﬂupirtine: from 32.7±1.8t o
10.5±0.8Hz; lamotrigine: from 32.4±1.3t o2 7 .0±1.7Hz).
3.4. Eﬀects of KCNQ Openers on Rise of the Slope of the
Action Potential. To determine whether KCNQ4 openers af-
fect the sodium channel, the maximum rise slopes of
action potentials were measured. The results showed that
retigabine and ﬂupirtine are unable to aﬀect the maximum
rise slope of action potentials (427.1 ± 10.1mV/ms and
386.3 ± 19.8mV/ms, before and after treatment with reti-
gabine, resp.; 427.6 ± 29.1mV/ms and 395.9 ± 20.1mV/ms,
before and after treatment with ﬂupirtine, resp.) (Figure 7).
Lamotrigine slightly but signiﬁcantly inhibits the maximum
rise slope of action potentials (440.9 ± 21.0 and 345.4 ±
21.8mV/ms, before and after treatment with lamotrigine,
resp.) (Figure 7).
4. Discussion
Mutations in the CLCN1 gene cause membrane hyperex-
citability in skeletal muscle. The resulting transient muscle
stiﬀnessischaracterisedbyinvoluntaryaftercontractionsand
a slowed relaxation (myotonia). This condition can also be
recapitulatedexperimentallybyblockingmembranechloride
(Cl−) channels of normal muscle with 9-anthracene car-
boxylic acid (9-AC) [29, 31–33]. 9-AC causes the repetitive
ﬁring of action potentials in mammalian skeletal muscle
membranes and thus induces slowed relaxation in skeletal
muscle. We applied 9-AC (0.1mM) to mouse skeletal muscle
to produce an animal model of myotonia. In the present
study, we compared the eﬀects of retigabine, ﬂupirtine,
and lamotrigine on 9-AC-induced myotonia in mouse
skeletal muscle. Our results showed that retigabine and
ﬂupirtine, but not lamotrigine, can signiﬁcantly reduce the
myotonic membrane hyperexcitability induced by 9-AC.
Because retigabine and ﬂupirtine did not cause changes in
the rise slope of the action potentials, the eﬀects of retigabine
and ﬂupirtine were not similar with sodium (Na+) channel
blockers. It has been reported that retigabine is a selective
Kv7 (KCNQ) potassium channel opener [34–36], which can
act as an anticonvulsant by reducing excitability through
the stabilisation of the neuronal membrane. Flupirtine also8 Evidence-Based Complementary and Alternative Medicine
acts as a Kv7 channel opener and is a centrally acting,
nonopioid analgesic with muscle relaxant properties that
is advocated for use in a number of pain conditions
[37]. Confocal immunoblotting analysis of the mammalian
skeletal sarcolemma demonstrated the distribution of Kv
7 . 2a n dK v7 . 3t ob ei nZ - l i n ea n dK v7 . 4e x p r e s s i o nt o
be restricted to the plasma membrane [25]. From these
data, it appeared that KCNQ proteins existed on the plasma
membranes of skeletal muscle. However, it is not known
whether the KCNQ openers can eﬀectively reduce the
membrane overexcitability of mammalian skeletal muscle.
In this experiment, we demonstrated that ﬂupirtine, and
retigabine can inhibit the membrane excitability of skeletal
muscle induced by 9-AC, and these eﬀects can be reversed by
treatment with the KCNQ blocker linopirdine. Lamotrigine,
aN a + blocker in the central nervous system that acts without
eﬀectsonKCNQchannels,hasalessereﬀectonthereduction
of excitability induced by 9-AC. Therefore, ﬂupirtine and
retigabine inhibit membrane excitability induced by 9-AC
through eﬀects on the KCNQ channel rather than on the
blockade of the Na+ channel. In clinical practice, various
Na+ channel blockers have been used to treat myotonia, such
as carbamazepine, mexiletine, phenytoin, and procainamide.
Mexiletine is the drug of choice for reducing myotonia
in myotonic dystrophy type I [38]. Na+ channel blockers
have some unwanted eﬀects, including a tendency to reduce
muscle force by decreasing muscle action potentials. A
Cl− channel opener is not currently available for our use;
therefore, we are utilising Na+ channel blockers to treat
myotonia. Although lamotrigine has been shown to act at
voltage-sensitive Na+ channels and stabilise neural mem-
branes, it has a lesser eﬀect on muscle myotonia as compared
with KCNQ openers (e.g., retigabine and ﬂupirtine). The
eﬀect of lamotrigine may be more selective in the central
nervous system than in peripheral tissues. Evidence from
this study suggests that KCNQ openers may be a new class
of drugs for the treatment of myotonia. Because retigabine
and ﬂupirtine cannot signiﬁcantly change the rise slope of
action potentials, the unwanted eﬀects on Na+ channels can
thus be excluded. All of these studies indicate that retigabine
and ﬂupirtine may be considered useful in the treatment of
myotonia.
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